Topic: Cancer Treatment

The emotional display between Travis Kelce and Taylor Swift on the field is contrasted with Kelce's performance of "Viva Las Vegas." Pfizer's Super Bowl advertisement, which utilized music by the band Queen, is criticized for using the legacy of the late Freddie Mercury to promote pharmaceutical interests and future cancer treatments.

The FDA has approved the first "biosimilar" drug, a low-cost version of the biotech drug Neupogen used for cancer patients. Unlike traditional generics, biosimilars are derived from living organisms; the discussion notes that the lack of transparent pricing for these drugs allows biotech firms to maintain high costs, exemplified by a recent $21 billion company buyout.

The segment revisits the hosts' prediction that IBM's Watson would be used to automate healthcare decisions, citing new reports on its role in cancer research. They also discuss the inclusion of "Sensory Processing Disorder" in the DSM-5, suggesting it is a way to pathologize and medicate normal childhood behaviors.

The hosts discuss a UK High Court ruling that forced a seven-year-old boy, Neon Roberts, to undergo brain surgery and radiotherapy against his mother's wishes. Dvorak questions the efficacy of "radiotherapy," calling it a misnomer for radiation.

The FDA issued a warning regarding counterfeit versions of the cancer drug Avastin appearing in the U.S. supply chain. A 60 Minutes report by Sanjay Gupta further highlights the global trade in counterfeit prescription medications, estimated at $75 billion annually.

The hosts read letters from donors, including Elizabeth Solieri, who redirected her United Way contributions to the No Agenda show. A donation from John Matthews mentions the "Burzynski" documentary, which details a doctor's struggle with the FDA over alternative cancer treatments. The hosts express interest in reviewing the film after the filmmaker reached out to the show.

An analysis from the Economic Policy Journal suggests the healthcare bill mandates government audits of self-insured employers and creates a committee to decide treatment benefits. The report claims the legislation could lead to the rationing of care at cancer hospitals and restrict hospital expansions.